NASDAQ$KIDS
OrthoPediatrics Corp · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
OrthoPediatrics experienced revenue growth and strategic advancements.
OrthoPediatrics Corp. reported a strong fourth quarter and full year 2019, marked by a 30.1% increase in Q4 revenue to $19.0 million and a 26.0% increase in full-year revenue to $72.6 million. The company launched new products, expanded its sales organization, and strengthened its cash position through a follow-on offering.
- Total revenue increased to $19.0 million, up 30.1% from Q4 2018.
- Trauma and Deformity revenue grew by 34%, Scoliosis by 21%, and Sports Medicine/Other by 18%.
- Launched PediFoot Deformity Correction System and QuickPack™ bone graft substitute.
- Strengthened cash position with $60 million in net proceeds from follow-on offering.
Headline financials
Revenue & EPS history
OrthoPediatrics · Revenue · Quarterly
$19M
Revenue by segment
OrthoPediatrics · $19M total across 3 segments · Q4 2019
- Trauma and Deformity$13.6M+34.3%71.9%
- Scoliosis$4.89M+20.7%25.8%
- Sports Medicine/Other$430K+17.8%2.3%
Forward guidance
OrthoPediatrics provided full year 2020 revenue guidance of growth in the range of 22%-24% and investment in consignment sets to be in a range of $19-$21 million.
Tailwinds
- Revenue growth in a range of 22% to 24% year-over-year
- Investing $19-$21 million in consigned sets for 2020
- Focus on deploying capital-efficient systems
- Realizing the revenue impact from the full roll-out of recent product launches
- Commitment to pediatric-specific surgical solutions
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2019
-0.6%
Avg return
Earnings day
-1.0%
Avg return
5 days after
-0.4%
Avg return
30 days after
50%
17 / 34 earnings
Positive
+13.1%
Q2 2022
Best reaction
-13.0%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.8% | +13.7% | +14.0% | |
| Q4 2025 | +8.3% | +3.9% | -12.8% | |
| Q3 2025 | -2.6% | -3.0% | +9.3% | |
| Q1 2025 | +4.0% | +4.6% | -4.5% | |
| Q4 2024 | +11.9% | +7.0% | -0.8% | |
| Q3 2024 | -7.8% | -16.2% | -22.3% | |
| Q2 2024 | -7.8% | -9.0% | +3.8% | |
| Q1 2024 | +5.7% | -5.3% | -1.9% | |
| Q4 2023 | +5.4% | +1.9% | +0.8% | |
| Q3 2023 | +4.2% | -5.1% | +8.9% | |
| Q2 2023 | -4.6% | -4.9% | -7.2% | |
| Q1 2023 | -7.5% | -8.0% | -14.4% | |
| Q4 2022 | +0.5% | +1.7% | -0.8% | |
| Q3 2022 | -13.0% | -12.4% | +0.8% | |
| Q2 2022 | +13.1% | +19.2% | -0.8% | |
| Q1 2022 | -10.2% | -17.7% | -8.1% | |
| Q4 2021 | -5.8% | -6.3% | -2.0% | |
| Q3 2021 | +2.0% | +0.4% | -19.4% | |
| Q2 2021 | +6.9% | +4.5% | +9.2% | |
| Q1 2021 | +10.1% | +4.4% | +4.4% | |
| Q4 2020 | -7.1% | -8.6% | +2.3% | |
| Q3 2020 | -6.5% | +6.5% | -2.1% | |
| Q2 2020 | +4.7% | +9.7% | -0.6% | |
| Q1 2020 | +2.8% | +4.8% | +10.0% | |
| Q4 2019 | +1.1% | -4.5% | -19.5% | |
| Q3 2019 | +5.7% | +8.9% | +10.6% | |
| Q2 2019 | -0.2% | -1.0% | +10.9% | |
| Q1 2019 | -9.5% | -10.3% | -8.3% | |
| Q4 2018 | -4.3% | -2.0% | -6.2% | |
| Q3 2018 | -12.5% | -16.0% | -11.4% | |
| Q2 2018 | +2.7% | +2.7% | +23.7% | |
| Q1 2018 | -1.1% | +1.9% | +32.0% | |
| Q4 2017 | -1.9% | +3.4% | -2.9% | |
| Q3 2017 | -11.3% | -2.0% | -8.5% | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q1 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro